Cellectis(CLLS) GlobeNewswire News Room·2024-11-05 21:30Core Insights - Cellectis is presenting pre-clinical data aimed at enhancing CAR T cell activity against solid tumors while minimizing potential toxicity at the Society for Immunotherapy of Cancer's 39th Annual Meeting [1][2] Group 1: Presentation Details - The data will be presented in a poster titled "Breaking barriers in solid tumors with SMART allogeneic CAR T-cells" on November 9th, 2024, from 9:00 am to 8:30 pm ET by Beatriz Aranda-Orgilles [2] - The poster number is 254 [2] Group 2: Challenges in Solid Tumors - Despite the success of CAR T-cell therapies in treating blood cancers, challenges remain in solid tumors due to the hostile tumor microenvironment (TME) which creates an immunosuppressive barrier [2] - Factors such as tumor antigen diversity and low expression of CAR-targeted tumor-associated antigens (TAA) can lead to antigen escape or on-target off-tumor toxicity, complicating therapeutic safety [2] Group 3: Innovative Strategies - Cellectis employs TALEN®-mediated gene editing to generate allogeneic CAR T-cells, repurposing PD-1 function to enhance efficacy and avoid toxicities in solid tumors [3] - The company integrates IL-12 into PD-1 regulatory elements to confine IL-12 to the TME and inactivates TGFBR2 to overcome TGFB1-mediated resistance, enhancing CAR T-cell proliferation and infiltration while reducing tumor burden [4] Group 4: Potential Impact - The data suggests the potential of creating armored allogeneic CAR T-cells with improved activity in immunosuppressive microenvironments, offering a therapeutic option for patients with solid malignancies [5] Group 5: Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform [5] - The company specializes in an allogeneic approach for CAR-T immunotherapies, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [5]